Recent News

• 05.06.2025 - OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
• 05.06.2025 - OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
• 04.30.2025 - Jonathan Miller
• 04.30.2025 - Jonathan Miller
• 04.08.2025 - Stifel Targeted Oncology Forum
• 04.08.2025 - Stifel Targeted Oncology Forum
• 03.11.2025 - Leerink's Global Healthcare Conference 2025
• 03.11.2025 - Leerink's Global Healthcare Conference 2025
• 03.10.2025 - OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
• 03.10.2025 - OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Recent Filings

• 04.16.2025 - ARS Annual Report to Security Holders
• 04.16.2025 - DEF 14A Other definitive proxy statements
• 04.16.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.24.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.21.2025 - EFFECT Notice of Effectiveness
• 03.20.2025 - POS AM Post-Effective amendments for registration statement